Essex Bio-Technology Management
Management criteria checks 4/4
Essex Bio-Technology's CEO is Malcolm Ngiam, appointed in Jul 2025, has a tenure of less than a year. total yearly compensation is HK$1.80M, comprised of 86.1% salary and 13.9% bonuses, including company stock and options. directly owns 0.36% of the company’s shares, worth HK$8.48M. The average tenure of the management team and the board of directors is 7.8 years and 5.4 years respectively.
Key information
Malcolm Ngiam
Chief executive officer
HK$1.8m
Total compensation
| CEO salary percentage | 86.09% |
| CEO tenure | less than a year |
| CEO ownership | 0.4% |
| Management average tenure | 7.8yrs |
| Board average tenure | 5.4yrs |
Recent management updates
Recent updates
Essex Bio-Technology's (HKG:1061) Shareholders Will Receive A Bigger Dividend Than Last Year
Aug 29
Most Shareholders Will Probably Find That The Compensation For Essex Bio-Technology Limited's (HKG:1061) CEO Is Reasonable
May 14A Look At The Fair Value Of Essex Bio-Technology Limited (HKG:1061)
Apr 29Essex Bio-Technology Limited (HKG:1061) Stock Catapults 26% Though Its Price And Business Still Lag The Market
Mar 28Essex Bio-Technology Limited (HKG:1061) Surges 29% Yet Its Low P/E Is No Reason For Excitement
Oct 09Essex Bio-Technology's (HKG:1061) Upcoming Dividend Will Be Larger Than Last Year's
Aug 29Essex Bio-Technology Limited's (HKG:1061) Low P/E No Reason For Excitement
May 06Calculating The Fair Value Of Essex Bio-Technology Limited (HKG:1061)
Mar 21Essex Bio-Technology (HKG:1061) Has A Pretty Healthy Balance Sheet
Dec 07Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly
Dec 07Essex Bio-Technology (HKG:1061) Is Due To Pay A Dividend Of HK$0.04
Aug 25Is Essex Bio-Technology (HKG:1061) Using Too Much Debt?
Jun 22Essex Bio-Technology (HKG:1061) Has Announced That It Will Be Increasing Its Dividend To HK$0.055
May 02Essex Bio-Technology (HKG:1061) Will Pay A Larger Dividend Than Last Year At HK$0.055
Mar 30Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly
Jun 29Is Essex Bio-Technology (HKG:1061) A Risky Investment?
Mar 31If You Had Bought Essex Bio-Technology (HKG:1061) Stock Five Years Ago, You Could Pocket A 40% Gain Today
Mar 13How Many Essex Bio-Technology Limited (HKG:1061) Shares Did Insiders Buy, In The Last Year?
Feb 15
Do Institutions Own Essex Bio-Technology Limited (HKG:1061) Shares?
Jan 25Essex Bio-Technology Limited's (HKG:1061) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?
Jan 04Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly
Dec 13Why Essex Bio-Technology's (HKG:1061) CEO Pay Matters
Nov 23CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2025 | n/a | n/a | HK$313m |
| Mar 31 2025 | n/a | n/a | HK$310m |
| Dec 31 2024 | HK$2m | HK$2m | HK$307m |
| Sep 30 2024 | n/a | n/a | HK$285m |
| Jun 30 2024 | n/a | n/a | HK$263m |
| Mar 31 2024 | n/a | n/a | HK$269m |
| Dec 31 2023 | HK$2m | HK$2m | HK$275m |
| Sep 30 2023 | n/a | n/a | HK$266m |
| Jun 30 2023 | n/a | n/a | HK$256m |
| Mar 31 2023 | n/a | n/a | HK$241m |
| Dec 31 2022 | HK$2m | HK$2m | HK$225m |
| Sep 30 2022 | n/a | n/a | HK$274m |
| Jun 30 2022 | n/a | n/a | HK$323m |
| Mar 31 2022 | n/a | n/a | HK$334m |
| Dec 31 2021 | HK$2m | HK$2m | HK$346m |
| Sep 30 2021 | n/a | n/a | HK$339m |
| Jun 30 2021 | n/a | n/a | HK$332m |
| Mar 31 2021 | n/a | n/a | HK$275m |
| Dec 31 2020 | HK$688k | HK$307k | HK$219m |
Compensation vs Market: Malcolm's total compensation ($USD229.92K) is below average for companies of similar size in the Hong Kong market ($USD363.23K).
Compensation vs Earnings: Malcolm's compensation has been consistent with company performance over the past year.
CEO
Malcolm Ngiam (40 yo)
Mr. Hian Leng Ngiam, also known as Malcolm, serves as Executive Director at Essex Bio-Technology Limited since September 19, 2020 and its CEO since July 1, 2025. He was Deputy Managing Director at Essex Bi...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder & Chairman | no data | HK$3.23m | 52.79% HK$ 1.2b | |
| CEO & Executive Director | less than a year | HK$1.80m | 0.36% HK$ 8.5m | |
| Executive Director | less than a year | HK$1.83m | 0.92% HK$ 21.8m | |
| Executive Director & Company Secretary | 25.1yrs | HK$737.38k | 0.0081% HK$ 191.3k | |
| Group Chief Scientific Officer | 7.8yrs | no data | no data |
Experienced Management: 1061's management team is seasoned and experienced (7.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder & Chairman | no data | HK$3.23m | 52.79% HK$ 1.2b | |
| CEO & Executive Director | 5.4yrs | HK$1.80m | 0.36% HK$ 8.5m | |
| Executive Director | no data | HK$1.83m | 0.92% HK$ 21.8m | |
| Executive Director & Company Secretary | 5.4yrs | HK$737.38k | 0.0081% HK$ 191.3k | |
| Independent Non Executive Director | 24.7yrs | HK$250.00k | no data | |
| Independent Non Executive Director | 21.4yrs | HK$220.00k | no data | |
| Independent Non-Executive Director | 2.7yrs | HK$220.00k | no data |
Experienced Board: 1061's board of directors are considered experienced (5.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/10 10:13 |
| End of Day Share Price | 2026/02/10 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Essex Bio-Technology Limited is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Xiao Wei Lin | Everbright Securities Co. Ltd. |
| null null | Guoyuan Securities (HK) Ltd |
| Stella Xing | Nomura Securities Co. Ltd. |